Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

NFlection presents positive phase IIa data for NFX-179 gel

May 27, 2021

Connect begins phase I trial of CBP-174 for chronic inflammatory pruritus

May 26, 2021

Sonelokimab shows significant clinical benefit over placebo in patients with plaque psoriasis

May 26, 2021

Incyte initiates phase II study of INCB-054707 in nonsegmental vitiligo

May 21, 2021

First patients dosed in phase I study of PBI-100

May 21, 2021

Olix initiates phase II study of OLX-10010 as treatment of hypertrophic scars

May 21, 2021

China's NMPA approves phase I trial of InnoCare's TYK2 inhibitor ICP-332

May 19, 2021

Phase III trials of ruxolitinib in vitiligo meet endpoints

May 17, 2021

Dosing begins in phase II trial of CGB-400 for rosacea

May 14, 2021

Reistone begins phase III trial of oral SHR-0302 in moderate to severe atopic dermatitis

May 12, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...